Eye News and Research

Latest Eye News and Research

Students live with elder residents as part of the Learning by Living project

A geriatric training method pioneered by Marilyn R. Gugliucci, PhD, president of the Association for Gerontology in Higher Education (the educational branch of The Gerontological Society of America) has proved successful enough that she plans to implement it on a national level.

25 Sep 2009

Children with minimal change nephrotic syndrome can be treated with prednisone

A kidney condition that can arise in children and was until recently believed to disappear after puberty may persist into adulthood and cause significant long-term complications, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The findings indicate that better treatment options are needed for children with the disorder, called minimal change nephrotic syndrome.

25 Sep 2009

Commitments announced at the Clinton Global Initiative

The second day of the Fifth Annual Meeting of the Clinton Global Initiative (CGI) came to a close with a special session on Northern Ireland, following afternoon plenary and breakout sessions that focused on harnessing innovation for development.

24 Sep 2009

ThromboGenics completes enrollment for MIVI-TRUST clinical trial

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that it has completed the enrolment of the US Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease.

24 Sep 2009

Enrollment for pSivida's pilot FAVOR clinical study commences

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien in patients with macular edema secondary to retinal vein occlusion.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

Stay Fresh textiles technology from Quick-Med

Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today the development of a proprietary Stay Fresh™ technology and that the Company is seeking partners to commercialize this revolutionary new technology in key segments of the textile market.

23 Sep 2009

Researchers make significant advances in the treatment of metastatic malignant melanoma

Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.

23 Sep 2009

Advancements in the treatment of metastatic malignant melanoma

23 Sep 2009

Autism Treatment Center of America announces Son-Rise Program lecture dates

Raun K.Kaufman, CEO of the Autism Treatment Center of America and Advisory Board Member of the United States Autism & Asperger's Association (USAAA), announces a series of lecture dates to be held this autumn in the UK. The Son-Rise Program of the Autism Treatment Center of America has assisted parents worldwide and in the UK dealing with Autism Spectrum Disorders including Alison Taylor.

23 Sep 2009

Update from Advanced Cell on pre-clinical activities for its RPE cell program

Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) provided an update on pre-clinical activities in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases.

23 Sep 2009

Pelosi says House health bill will have public option

'No bill can pass the House of Representatives without a public option in it,' Pelosi, D-Calif., said at a press conference after a private tour of Thomas Jefferson University Hospital with a group of physicians and local Congressional Democrats.

23 Sep 2009

Gerresheimer opens new R&D and production centers in USA and Europe

The Gerresheimer Group expands its activities in the pharmaceutical plastic business with two strategically significant investments in the USA and Europe. This week the company is almost simultaneously opening a new research and development center for medical plastic systems in the USA as well as a new production center for pharmaceutical plastic packaging in Spain.

22 Sep 2009

WDS conducts free skin cancer screenings

In the most concentrated effort to promote sun safety and skin cancer prevention in the 35-year history of the Women's Dermatologic Society (WDS), volunteer dermatologists in three states recently provided free skin cancer screenings and sun safety education to spectators, professional athletes and media members at four major golf and tennis events throughout the month of August.

22 Sep 2009

Gerresheimer opens new R&D and production centers in USA and Europe

The Gerresheimer Group expands its activities in the pharmaceutical plastic business with two strategically significant investments in the USA and Europe.

22 Sep 2009

Matching parent-child pairs not dependent on race or culture

Scientists have ample evidence that individuals use a variety of cues to identify their own kin. People can also detect resemblances in families other than their own. A new study shows that their success in doing so is the same, whether or not those families are the same race as themselves.

22 Sep 2009

Gene variant discovery could lead to future glaucoma treatments

An international team, led by researchers from the University of California, San Diego School of Medicine and the National Eye Institute, has discovered gene variants for glaucoma in a black population. The finding could lead to future treatments or a cure for this disease, which leads to blindness in two million Americans each year.

22 Sep 2009

New device for identifying eye conditions in infants

Tell-tale signs of a condition that can blind premature babies are being seen for the first time using a new handheld device in a study at Duke University Medical Center.

22 Sep 2009

HearAtLast Holdings opens new tinnitus clinic in Canada

(PINKSHEETS: HRAL) HearAtLast Holdings, Inc., a leading provider of suitable affordable solutions to clients with hearing needs in the billion dollar hearing loss market, announced today that the Company is in the final development stage of a new Tinnitus Clinic located in the prominent Kingsway Community of Toronto, Ontario Canada.

22 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009